MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Summary
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Timeline
- Start
- 2024-06-18
- Primary completion
- 2029-05-15
- Completion
- 2029-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Intravenous |
| Subject | Busulfan | Small molecule | — | Intravenous |
| Subject | CPX-351 | Other / unclassified | — | Intravenous |
| Subject | Cytarabine | Small molecule | — | Intravenous |
| Subject | Daunorubicin | Small molecule | — | Intravenous |
| Subject | Decitabine and Cedazuridine | Unknown | — | Oral |
| Subject | Emavusertib | Small molecule | — | Oral |
| Subject | Enasidenib | Small molecule | — | Oral |
| Subject | Fludarabine | Small molecule | — | Intravenous |
| Comparator | Gemtuzumab Ozogamicin | Monoclonal antibody | — | Intravenous |
| Subject | Gilteritinib | Small molecule | — | Oral |
| Subject | Luspatercept | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Melphalan | Small molecule | — | Intravenous |
| Subject | Olutasidenib | Small molecule | — | Oral |
| Subject | Venetoclax | Small molecule | — | Oral |
| Subject | epoetin alfa | Protein / enzyme biologic | — | Subcutaneous |